Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1807 results
February 2015
-
Media ReleaseNovartis shareholders approve all resolutions proposed by Novartis Board of DirectorsShareholders approve 18th consecutive dividend increase to CHF 2.60 (+6%) per share for 2014 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well…
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administrationLes actionnaires approuvent la 18e hausse consécutive du dividende, à CHF 2,60 par action (+6 %) au titre de l'exercice 2014. De même que d'autres administrateurs qui étaient candidats à leur…
-
Media ReleaseAktionäre genehmigen alle Anträge des Verwaltungsrats von NovartisAktionäre genehmigen für 2014 die 18. Dividendenerhöhung in Folge auf CHF 2,60 pro Aktie (+6%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats sowie alle weiteren Mitglieder des…
-
Media ReleaseNovartis lung cancer drug Zykadia® recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinibIf approved, Zykadia (ceritinib) would be the first treatment option for patients in Europe with ALK+ NSCLC previously treated with crizotinib ALK+ NSCLC is driven by a rearrangement of the…
-
Why research into rare diseases matters
Hundreds of millions of people worldwide await treatments for rare diseases.
-
Chemical genetics: The sleuthing behind modern drug discovery
Researchers at Novartis are combining modern techniques with an old approach to drug discovery and getting surprising results.
-
Media ReleaseNovartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myelomaFarydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD[1] Farydak prolonged median…
-
Researchers aim to beat trick play by tumors with drug combo
-
Media ReleaseNovartis' heart failure medicine LCZ696 granted FDA priority reviewDecision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months Filing is based on results from the landmark PARADIGM-HF study[1] …
-
Media ReleaseAlcon receives FDA approval of Pazeo(TM) Solution for ocular allergy itch reliefUS Food and Drug Administration grants approval of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7% for sale in the United States Developed with efficacy data at 24 hours, post dose…
January 2015
-
Media ReleaseNovartis announces study in NEJM showing Jakavi® was superior to standard therapy in rare blood cancer polycythemia veraJakavi® (ruxolitinib) treatment resulted in durable hematocrit control, spleen size reduction and symptom relief for patients with uncontrolled polycythemia vera[1] Polycythemia vera (PV) is…
-
Media ReleaseNovartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businessesNet sales grew in FY 2014, with strong core[1] margin expansion Net sales increased 1% (+3% cc[1])[2] to USD 58.0 billion in FY (Q4: -2%, +4% cc) Operating income grew 1% (+7% cc) to USD 10.7…
Pagination
- ‹ Previous page
- 1
- …
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- …
- 151
- › Next page